Patients who switched to Gla‐300 were less likely to experience hypoglycaemia at 3‐month follow‐up (odds ratio [OR] 0.56, 95% CI 0.32‐0.97; P = 0.039) and at 6‐month follow‐up (OR 0.58, 95% CI 0.38‐0.87; P = 0.009) compared with patients who switched to other basal insulins. This evidence concerns the gene INS and Hypoglycemia.